Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-11-25 Sale |
2024-11-27 5:06 pm |
Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer |
1,010 | $16.02 | $16,177 | 172,460 (Indirect Direct) |
View |
| 2024-11-18 Sale |
2024-11-20 5:07 pm |
Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer |
6,190 | $16.38 | $101,421 | 173,470 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-14 Option Award |
2025-03-17 4:12 pm |
N/A 2035-03-13 |
Contineum Therapeutics Inc. | CTNM | Miralles Gines Diego Director |
29,500 | $0 | 29,500 (Direct) |
View |
Ownership |
2025-03-17 4:10 pm |
N/A 2034-06-09 |
Contineum Therapeutics Inc. | CTNM | Miralles Gines Diego Director |
0 | $0 | 5,000 (Direct) |
View |
| 2025-01-31 Option Award |
2025-01-31 4:41 pm |
N/A 2035-01-30 |
Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec |
63,589 | $0 | 63,589 (Direct) |
View |
| 2025-01-31 Option Award |
2025-01-31 4:40 pm |
N/A 2035-01-30 |
Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer |
110,000 | $0 | 110,000 (Direct) |
View |
| 2025-01-31 Option Award |
2025-01-31 4:38 pm |
N/A 2035-01-30 |
Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer |
113,700 | $0 | 113,700 (Direct) |
View |
| 2025-01-31 Option Award |
2025-01-31 4:38 pm |
N/A 2035-01-30 |
Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. |
110,000 | $0 | 110,000 (Direct) |
View |
| 2025-01-31 Option Award |
2025-01-31 4:35 pm |
N/A 2035-01-30 |
Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President |
300,000 | $0 | 300,000 (Direct) |
View |
| 2024-08-13 Exercise |
2024-08-14 6:03 pm |
N/A 2030-02-24 |
Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. |
12,800 | $0 | 174,194 (Direct) |
View |
| 2024-08-13 Exercise |
2024-08-14 6:03 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. |
12,800 | $1.01 | 174,194 (Direct) |
View |
| 2024-06-24 Option Award |
2024-06-24 4:25 pm |
N/A 2034-06-23 |
Contineum Therapeutics Inc. | CTNM | Boyce Sarah Director |
29,500 | $0 | 29,500 (Direct) |
View |
| 2024-06-03 Option Award |
2024-06-03 5:46 pm |
N/A 2034-06-02 |
Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec |
160,000 | $0 | 160,000 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:59 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President |
285,000 | $0 | 285,000 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:58 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer |
100,000 | $0 | 100,000 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:58 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer |
103,700 | $0 | 103,700 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:56 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. |
100,000 | $0 | 100,000 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:56 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Ignelzi Troy A. Director |
6,350 | $0 | 6,350 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:55 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Ware Olivia C Director |
3,700 | $0 | 3,700 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:54 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Lyons-Williams Lori Director |
29,500 | $0 | 29,500 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:54 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Brady Todd R. Director |
29,500 | $0 | 29,500 (Direct) |
View |
| 2024-05-24 Option Award |
2024-05-29 5:53 pm |
N/A 2034-05-23 |
Contineum Therapeutics Inc. | CTNM | Schimmelpennink Evert B. Director |
29,500 | $0 | 29,500 (Direct) |
View |
| 2024-05-20 Option Award |
2024-05-20 7:00 pm |
N/A 2034-05-19 |
Contineum Therapeutics Inc. | CTNM | Ignelzi Troy A. Director |
23,150 | $0 | 23,150 (Direct) |
View |
| 2024-04-09 Conversion |
2024-04-11 6:10 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC 10% Owner |
5,483,756 | $0 | 10,101,912 (Indirect) |
View |
Ownership |
2024-04-10 5:05 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | JOHNSON & JOHNSON Johnson & Johnson Innovation - JJDC Inc. 10% Owner |
0 | $0 | 1,979,173 (Indirect) |
View |
Ownership |
2024-04-04 9:22 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
0 | $0 | 5,316,663 (Direct) |
View |
Ownership |
2024-04-04 5:59 pm |
N/A 2034-03-26 |
Contineum Therapeutics Inc. | CTNM | Ware Olivia C Director |
0 | $0 | 29,479 (Direct) |
View |
Ownership |
2024-04-04 5:59 pm |
N/A 2032-01-17 |
Contineum Therapeutics Inc. | CTNM | Schimmelpennink Evert B. Director |
0 | $0 | 32,090 (Direct) |
View |
Ownership |
2024-04-04 5:58 pm |
N/A 2030-08-11 |
Contineum Therapeutics Inc. | CTNM | Lyons-Williams Lori Director |
0 | $0 | 29,478 (Indirect) |
View |
Ownership |
2024-04-04 5:56 pm |
N/A 2034-03-26 |
Contineum Therapeutics Inc. | CTNM | Brady Todd R. Director |
0 | $0 | 29,479 (Direct) |
View |
Ownership |
2024-04-04 5:54 pm |
N/A 2030-02-24 |
Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. |
0 | $0 | 236,725 (Direct) |
View |
Ownership |
2024-04-04 5:52 pm |
N/A 2030-10-05 |
Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer |
0 | $0 | 237,618 (Direct) |
View |
Ownership |
2024-04-04 5:51 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer |
0 | $0 | 670,865 (Direct) |
View |
Ownership |
2024-04-04 5:49 pm |
N/A N/A |
Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President |
0 | $0 | 981,519 (Direct) |
View |